Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00255099
Status:
COMPLETED
Last Update Posted:
2011-06-15
First Post:
2005-11-15
Brief Title:
TMC125-C216 A Phase III Study to Investigate the Efficacy Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen Including TMC114Ritonavir and an Investigator-selected Optimized Background in HIV-1 Infected Patients With Limited to no Treatment Options
Sponsor:
Tibotec Pharmaceuticals Ireland
Organization:
Tibotec Pharmaceuticals Ireland
Organization Data
Organization:
Tibotec Pharmaceuticals Ireland
Class:
INDUSTRY
Study ID:
CR006307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tibotec Pharmaceuticals Ireland
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Compound Development Team Leader TMC125
Old Organization:
Tibotec Pharmaceutical Limited